Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02804568
What this trial is testing

Safety Study in Adults With Schizophrenia

Who this might be right for
Schizophrenia
Alkermes, Inc. 42
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Testing effectiveness (Phase 2)Looking for participantsNCT04094610
What this trial is testing

Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid TumorsLymphoma+1 more
Turning Point Therapeutics, Inc. 75
Early research (Phase 1)Ended earlyNCT02511184
What this trial is testing

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Who this might be right for
ALK-positive Advanced NSCLC
Pfizer 9
Not applicableStudy completedNCT00907920
What this trial is testing

Studying Tumor Samples From Young Patients With Neuroblastoma

Who this might be right for
Neuroblastoma
Children's Oncology Group 1,500
Testing effectiveness (Phase 2)Active Not RecruitingNCT05845671
What this trial is testing

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Who this might be right for
Lung CancerNon Small Cell Lung Cancer
University of Colorado, Denver 12
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Not applicableStudy completedNCT01620853
What this trial is testing

Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Applied Spectral Imaging Ltd. 1
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Testing effectiveness (Phase 2)UnknownNCT04058470
What this trial is testing

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 140
Testing effectiveness (Phase 2)UnknownNCT06260553
What this trial is testing

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Who this might be right for
EGFR/ ALK-negative Advanced NSCLC
Fujian Cancer Hospital 40
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Not applicableLooking for participantsNCT06781905
What this trial is testing

Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Who this might be right for
Metastatic Lung CancerMetastatic Lung Cancer With ALK/ROS1 Fusion
Hospices Civils de Lyon 20
Not applicableLooking for participantsNCT02285582
What this trial is testing

International Rare Histiocytic Disorders Registry (IRHDR)

Who this might be right for
Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more
The Hospital for Sick Children 400
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Testing effectiveness (Phase 2)UnknownNCT03654027
What this trial is testing

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Guangxi Medical University 84
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Next Page